Longitudinal follow-up of biopsy-proven small fiber neuropathy.


Journal

Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146

Informations de publication

Date de publication:
10 2019
Historique:
received: 22 09 2018
revised: 19 07 2019
accepted: 21 07 2019
pubmed: 28 7 2019
medline: 15 1 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

Little is published on the prognosis of small fiber neuropathy (SFN). A retrospective analysis of 101 patients with biopsy proven SFN. Study participants included 87 patients with length-dependent SFN and 14 patients with non-length-dependent SFN. The average duration of symptoms was 3.2 years prior to SFN diagnosis, and the average follow-up duration after diagnosis was 6.2 years. Neuropathic pain was present in 98% of patients and in 84.2% of patients at the final visit. The average total number of pain medications ever used was 4.4 per patient. Signs of autonomic dysfunction were initially present in 24.8% of patients, but improved in most. Large fiber involvement was seen in 11.9% of patients. Small fiber neuropathy affected employment and ambulation status in 5.3% and 6.3% of patients, respectively. Small fiber neuropathy tends to be stable and rarely affects ambulation and employment status. Effective pain control remains a challenge.

Identifiants

pubmed: 31348533
doi: 10.1002/mus.26648
doi:

Substances chimiques

Analgesics 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

376-381

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Lauria G. Small fibre neuropathies. Curr Opin Neurol. 2005;18(5):591-597.
Themistocleous AC, Ramirez JD, Serra J, Bennett DL. The clinical approach to small fibre neuropathy and painful channelopathy. Pract Neurol. 2014;14(6):368-379.
Chan AC, Wilder-smith EP. Small fiber neuropathy: getting bigger! Muscle Nerve. 2016;53(5):671-682.
Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(Pt 7):1912-1925.
Flossdorf P, Haupt WF, Brunn A, et al. Long-time course of idiopathic small fiber neuropathy. Eur Neurol. 2018;79(3-4):161-165.
Tavee JO, Polston D, Zhou L, Shields RW, Butler RS, Levin KH. Sural sensory nerve action potential, epidermal nerve fiber density, and quantitative sudomotor axon reflex in the healthy elderly. Muscle Nerve. 2014;49(4):564-569.
Khoshnoodi MA, Truelove S, Burakgazi A, Hoke A, Mammen AL, Polydefkis M. Longitudinal assessment of small fiber neuropathy: evidence of a non-length-dependent distal axonopathy. JAMA Neurol. 2016;73(6):684-690.
Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60(1):108-111.
Bakkers M, Faber CG, Hoeijmakers JG, Lauria G, Merkies IS. Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve. 2014;49(3):329-336.
Gorson KC, Herrmann DN, Thiagarajan R, et al. Non-length dependent small fibre neuropathy/ganglionopathy. J Neurol Neurosurg Psychiatry. 2008;79(2):163-169.
Wolfe GI, Baker NS, Amato AA, et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol. 1999;56(5):540-547.
Pasnoor M, Dimachkie MM, Barohn RJ. Cryptogenic sensory polyneuropathy. Neurol Clin. 2013;31(2):463-476.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-1765.
Barohn R, Gejewski B, Pasnoor M, et al. Patient Assisted Intervention for Neuropathy: Comparison of treatment in real life situations (PAIN-CONTRoLS). Neurology. 2018;90(15 Suppl):P1.435.
De Sousa EA, Hays AP, Chin RL, Sander HW, Brannagan TH. Characteristics of patients with sensory neuropathy diagnosed with abnormal small nerve fibres on skin biopsy. J Neurol Neurosurg Psychiatry. 2006;77(8):983-985.
Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology. 2001;57(9):1701-1704.
Bednarik J, Vlckova-moravcova E, Bursova S, Belobradkova J, Dusek L, Sommer C. Etiology of small-fiber neuropathy. J Peripher Nerv Syst. 2009;14(3):177-183.
Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294-1299.
Kluding PM, Pasnoor M, Singh R, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012;26(5):424-429.

Auteurs

Steven MacDonald (S)

Department of Neurology, Cleveland Clinic, Cleveland, Ohio.

Tara L Sharma (TL)

Department of Neurology, Cleveland Clinic, Cleveland, Ohio.

Jianbo Li (J)

Department of Quantitative Health Sciences, Learner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

David Polston (D)

Department of Neurology, Cleveland Clinic, Cleveland, Ohio.

Yuebing Li (Y)

Department of Neurology, Cleveland Clinic, Cleveland, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH